Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with its investment in Hemfrid
Mandate

Vinge has advised Fidelio Capital in connection with its investment in Hemfrid

August 27, 2021 M&A IT, Telecommunications and Outsourcing Corporate Commercial Employment and Benefits Real Estate and Construction Intellectual Property

Vinge has advised Fidelio Capital AB in its majority investment in Hemfrid i Sverige AB, the leading player within the home service industry in Sweden, with a revenue exceeding MSEK 700 and more than 2,000 employees in 2020. The transaction is subject to customary regulatory approvals and is expected to be completed during the second half of 2021.

Vinge’s team consisted of, among others, Daniel Rosvall, Jonas Bergström, Joacim Rydergård, Filip Öhrner, Christa Anttila, Hannah Kajlinger, Annie Fällström and Amanda Steen (M&A), Karolina Fuhrman and Mika Jordan (Corporate Commercial and IT), Felizia Wiker (IPR), Gustav Lindgren and Carl Östlund (Employment), Karolina Cohrs (Real Estate), and Sara Dahlros Sköld (VDR Assistant).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026